Results 211 to 220 of about 113,768 (298)

Evaluating the optimal duration of medication treatment for opioid use disorder

Addiction, EarlyView.
Abstract Background and aims Clinicians have little guidance on the ideal length of time patients should remain on medication treatment for opioid use disorder (MOUD) before being able to safely discontinue MOUD. This study estimated how the risk of all‐cause mortality changes with the duration of MOUD, controlling for patient characteristics that ...
Corey J. Hayes, Rebecca A. Raciborski, Mahip Acharya, Nahiyan Bin Noor, Edward V. Nunes, T. John Winhusen   +5 more
wiley   +1 more source

Vaccination Strategies Against Hepatic Diseases: A Scoping Review. [PDF]

Vaccines (Basel)
Beyzaei Z, Geramizadeh B, Karimzadeh S, Weiskirchen R.   +3 more
europepmc   +1 more source

Alcoholic Hepatitis [PDF]

, 2020
openaire   +1 more source

Contingency management interventions for substance use and addictive behaviours: Review of the United Kingdom evidence base

Addiction, EarlyView.
Abstract Background and aims Substance use and other addictive behaviours including gambling remain major public health concerns in the UK. Despite the effectiveness of substance use treatment approaches, treatment adherence and success rates remain low.
Carol‐Ann Getty, Tricia McQuarrie, Eileen Brobbin   +2 more
wiley   +1 more source

New Challenges in the Study of Liver Diseases: From Molecular Pathogenesis to Therapeutic Approaches (3rd Edition). [PDF]

Biomedicines
Dongiovanni P, Meroni M.
europepmc   +1 more source

Zero tolerance for 0%? How should clinicians and other practitioners respond to the use of alcohol‐free and low‐alcohol products in higher risk groups

Addiction, EarlyView.
Abstract Alcohol‐free and low‐alcohol drinks (no/lo drinks) are now widely available and popular with consumers in high‐income countries; however, it is unclear whether clinicians and others working to prevent or treat severe alcohol‐related health problems should take a zero‐tolerance approach to these alcohol‐like products or encourage patients to ...
John Holmes, Christopher K. Oldroyd, Colin Drummond, Matt Field, Inge Kersbergen, Michael E. D. Allison   +5 more
wiley   +1 more source

[Alcoholic hepatitis].

Gaceta medica de Mexico, 1987
L, Martín-Abreu, L, Guevara, P, Alonso de Ruiz, H, Cruz-Ortiz, D, Kershenobich, A, Díaz Belmont, J, Escotto Velázquez   +6 more
openaire   +3 more sources

A Retrospective Analysis of Hepatic Disease Burden and Progression in a Hospital-Based Romanian Cohort Using Integrated Cross-Sectional and Longitudinal Data (2019-2023). [PDF]

J Clin Med
Dumitrache Păunescu A, Șuțan NA, Popescu Stegarus DI, Soare LC, Ponepal MC, Mihăescu CF, Bondoc MD, Atamanalp M, Țânțu AC, Pisoschi CG, Baniță IM, Țânțu MM.   +11 more
europepmc   +1 more source

Drug use among people in prison: A global review of epidemiology, harms and interventions

Addiction, EarlyView.
Abstract Background and aims People who use drugs are overrepresented in the criminal justice system. We aimed to provide a broad synthesis of the epidemiology, harms and interventions related to drug use and drug use disorders among incarcerated adults worldwide, and highlight gaps in evidence and practice.
Louis Favril, John Strang, Seena Fazel
wiley   +1 more source

Association between duration of alcohol consumption and risk of hematemesis in patients with alcoholic cirrhosis complicated by esophagogastric variceal bleeding: a case-control study. [PDF]

BMC Gastroenterol
Ding S, Lu S, Cui L, Li J, Qin X, Liu X.
europepmc   +1 more source